Theralase Technologies Inc. Stock News

Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) announced it has received a Canadian patent for its cancer vaccine. The newly issued patent follows the previous issuance of a US patent in October

Theralase Technologies Inc. (OTCQX:TLTFF) Q4 2023 Earnings Conference Call April 3, 2024 11:00 AM ET Company Participants Matthew Perraton - Chairman of the Board Kristina Hachey - Chief Financial Off

Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) is eyeing regulatory approval for its lead asset, the bladder cancer treatment Rudivar, by 2026, according to its CFO. The Canadian pharmaceutical c

Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) announced that it will be hosting Advisory Board meetings at two upcoming urologic community forums to present data from its Phase 2 bladder cancer

Theralase Technologies Inc, a clinical-stage pharma company focused on photo-dynamic compounds, has donated two of its pioneering TLC-2400 Cool Laser Therapy (CLT) systems to the University of Win

Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) announced that Dr. Michael Jewett has joined the company as an independent consultant to assist it in completing patient enrollment for its Phase 2

A new treatment for bladder cancer could offer a higher quality of life for patients for an extended period of time compared to existing therapies. Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF),

Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) has released interim clinical data for its Phase II non-muscle invasive bladder cancer study indicating complete response rates exceeding Internatio

Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) is developing a drug targeting non-muscle invasive bladder cancer that CEO Roger DuMoulin-White says has shown super data compared to two Big Pharma

Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) is aiming to leverage positive study data during 3Q into a Breakthrough Therapy designation from the US Food and Drug Administration. The clinical-s

Theralase Technologies Inc. (V.TLT) hit a new 52-week high of 45.5 cents on Monday. Theralase has demonstrated proof-of-concept for the development of a Canadian-made SARS-CoV-2 vaccine. Atlas Engineered Products Ltd. (V.AEP) hit a new 52-week high of 66 cents on Monday. No news stories available today. Artis Real Estate Investment Trust (T.AX.UN) hit a new 52-week high of $12.45 on Monday. No news stories available today. Bri-Chem Corp. (T.BRY) hit a new 52-week high of 37 cents on Monday. No news stories available today. Colliers International Group Inc. (T.CIGI) hit a new 52-week high of $189.81 on Monday. No news stories available today. DREAM Unlimited Corp. (T.DRM) hit a new 52-week high of $41.39 on Monday. No news stories available today. Essential Energy Services Ltd. (T.ESN) hit a new 52-week high of 47 cents on Monday. No news stories available today. Great-West Lifeco Inc. (T.GWO) hit a new 52-week high of $40.87 on Monday. No news stories available today. Hydro One Limited (T.H) hit a new 52-week high of $33.15 on Monday.

TORONTO, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), A clinical stage pharmaceutical company dedicated to the res

TORONTO, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase® ” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the

TORONTO, June 11, 2021 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase® ” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the

TORONTO, May 28, 2021 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the rese